#1 Clinical Trials Search in Europe

Polydextrose

This article discusses the use of Polydextrose, a key component in a novel drug called PolyCore, which is being studied in clinical trials for the treatment of congestive heart failure. PolyCore is a solution for peritoneal dialysis that combines several active substances, including Polydextrose, to potentially improve outcomes for patients with heart failure and reduced kidney function. The trial aims to evaluate the effectiveness of Peritoneal Ultrafiltration with PolyCore in preventing heart failure exacerbation and improving patients’ quality of life.

Table of Contents

What is PolyCore?

PolyCore is a new medical solution being studied for the treatment of congestive heart failure. It is a solution for peritoneal dialysis, which means it’s a special liquid designed to be used inside the abdominal cavity.[1]

The solution contains several active ingredients:

  • Levocarnitine
  • Magnesium chloride hexahydrate
  • Sodium chloride (common salt)
  • Calcium chloride dihydrate
  • Lactic acid
  • Xylitol
  • Polydextrose

Each of these components plays a specific role in the treatment process.[1]

How PolyCore Works

PolyCore is used in a procedure called Peritoneal Ultrafiltration (PUF). This technique involves introducing the PolyCore solution into the abdominal cavity through a special catheter. The solution helps remove excess fluid from the body, which is a common problem in heart failure patients.[1]

The process works by using the peritoneum (the lining of the abdominal cavity) as a natural filter. The special composition of PolyCore helps draw out extra fluid from the bloodstream, which can then be drained from the body. This can help relieve symptoms of fluid overload, such as swelling and shortness of breath.[1]

Who Can Benefit from PolyCore?

PolyCore is being studied for patients with severe congestive heart failure. Specifically, it may be suitable for people who:

  • Have a left ventricular ejection fraction (a measure of how well the heart pumps) of 60% or less
  • Are classified as New York Heart Association (NYHA) class III-IV, which means they have significant limitations in physical activity due to their heart condition
  • Have decreased kidney function
  • Have high levels of certain heart failure markers in their blood (NT pro-BNP or BNP)
  • Have experienced episodes of fluid buildup requiring high-dose intravenous diuretics in the past

However, not everyone with heart failure will be eligible for this treatment. There are several conditions that might prevent someone from participating in the PolyCore study, such as recent heart surgery, severe kidney disease, or certain other medical conditions.[1]

The PURE Clinical Trial

PolyCore is currently being studied in a clinical trial called PURE (Peritoneal Ultrafiltration in Cardio Renal Syndrome to Prevent Heart Failure Exacerbation). This is a Phase II/III clinical trial, which means it’s testing both how well the treatment works and how safe it is.[1]

The main goal of the study is to see if PolyCore can help prevent deaths or worsening of heart failure symptoms. The researchers are also looking at several other factors, including:

  • Improvements in patients’ overall condition
  • Changes in quality of life
  • Changes in how much hospital care patients need
  • Effects on kidney function
  • Changes in urine output
  • How much diuretic medication patients need

The study will compare patients receiving PolyCore plus standard care to those receiving only standard care.[1]

Potential Benefits of PolyCore

If successful, PolyCore could offer several potential benefits for heart failure patients:

  • Reduced fluid buildup in the body, which could improve symptoms like shortness of breath and swelling
  • Fewer hospitalizations for heart failure symptoms
  • Improved kidney function
  • Better quality of life
  • Reduced need for high-dose diuretic medications

However, it’s important to remember that these potential benefits are still being studied and are not yet proven.[1]

Safety Considerations

As with any medical treatment, safety is a crucial consideration. The PURE study is carefully monitoring patients for any side effects or safety issues. Some potential risks could include:

  • Complications related to the catheter used for the peritoneal ultrafiltration
  • Infections
  • Imbalances in body chemicals or fluids

The researchers are closely tracking any adverse events, changes in vital signs, and results from physical examinations, ECGs, and laboratory tests to ensure patient safety.[1]

It’s important to note that PolyCore is still an experimental treatment. If you have congestive heart failure and are interested in this or other new treatments, you should discuss your options with your healthcare provider.

Aspect Details
Drug Name PolyCore (containing Polydextrose)
Trial Phase Phase II/III
Condition Studied Congestive Heart Failure
Main Objective Evaluate impact on mortality and patient condition
Treatment Method Peritoneal Ultrafiltration with PolyCore
Trial Duration Approximately 9 months
Key Inclusion Criteria Heart failure with reduced ejection fraction, decreased kidney function, elevated NT pro-BNP or BNP levels
Primary Endpoint Composite of mortality, hospitalization, increased diuretic need, and worsening renal function

FAQ

  • What is PolyCore and how does it relate to Polydextrose? PolyCore is a solution for peritoneal dialysis that contains several active substances, including Polydextrose. Polydextrose is one of the key components in PolyCore, which is being studied for its potential benefits in treating congestive heart failure.
  • What is the main objective of the clinical trial using PolyCore? The main objective of the trial is to evaluate if treatment with Peritoneal Ultrafiltration using PolyCore has an impact on patient mortality or worsening of patient condition in those with congestive heart failure.
  • Who can participate in this clinical trial? Participants must have congestive heart failure with specific criteria, including a left ventricular ejection fraction of 60% or less, NYHA Classification of III-IV, decreased kidney function, and elevated NT pro-BNP or BNP levels. They must also have experienced at least one episode of congestion requiring high-dose intravenous diuretics in the past 6 months.
  • How long does the clinical trial last? The trial consists of a screening period (up to 30 days), a treatment period of 210 days (about 7 months), and a long-term follow-up period of 60 days. In total, the trial lasts approximately 9 months.
  • What are some potential benefits of participating in this trial? Potential benefits may include improved heart function, better quality of life, reduced hospitalizations, and better management of fluid overload. However, it's important to note that benefits cannot be guaranteed, and participants will be closely monitored for any adverse effects.

Ongoing Clinical Trials on Polydextrose

  • Study on the Safety and Effectiveness of PolyCore (Xylitol, L-Carnitine, Polydextrin) for Patients with End-Stage Kidney Disease Starting Peritoneal Dialysis

    Recruiting

    2 1 1
    Investigated drugs:
    Italy

  • Study on Peritoneal Ultrafiltration with PolyCore for Patients with Congestive Heart Failure Using Levocarnitine and Drug Combination

    Recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Congestive Heart Failure: A condition where the heart cannot pump blood effectively, leading to fluid buildup in the body and various symptoms such as shortness of breath and fatigue.
  • Peritoneal Ultrafiltration: A method of removing excess fluid from the body using the lining of the abdominal cavity (peritoneum) as a natural filter.
  • PolyCore: A solution for peritoneal dialysis containing multiple active substances, including Polydextrose, being studied for the treatment of congestive heart failure.
  • Polydextrose: A synthetic polymer of glucose, used as one of the active substances in PolyCore.
  • NYHA Classification: New York Heart Association Classification, a system used to categorize the severity of heart failure symptoms.
  • NT pro-BNP: A hormone produced by the heart that is elevated in heart failure, used as a diagnostic marker.
  • BNP: Brain Natriuretic Peptide, another hormone produced by the heart that is elevated in heart failure.
  • GFR: Glomerular Filtration Rate, a measure of kidney function.
  • Loop diuretic: A type of medication used to remove excess fluid from the body by increasing urine production.
  • Cardio Renal Syndrome: A condition where heart and kidney dysfunction coexist and potentially worsen each other.

References

  1. http://clinicaltrials.eu/trial/study-on-peritoneal-ultrafiltration-with-polycore-for-patients-with-congestive-heart-failure-using-levocarnitine-and-drug-combination/